BioCentury
ARTICLE | Company News

AstraZeneca, Cancer Research U.K. deal

January 6, 2014 8:00 AM UTC

On Dec. 20, 2013, Cancer Research U.K.'s Drug Development Office ( DDO) and commercial subsidiary, Cancer Research Technology (CRT) Ltd., agreed to a clinical development partnership with AstraZeneca to develop the pharma's AZD2098 for kidney cancer. Under the deal, the DDO will fund and conduct preclinical trials and a Phase I trial in up to 40 kidney cancer patients. After the Phase I trial, which is slated to start in 2015, AstraZeneca will have the exclusive option to license the Phase I trial data and resume further development. If it does not exercise the option, the rights will be transferred to Cancer Research U.K., which can continue development or find an alternative partner. Cancer Research U.K. will be responsible for manufacturing AZD2098 for the Phase I trial, and AstraZeneca said it has provided the compound for continuing preclinical development. The partners declined to disclose further terms. ...